In vivo HIV-1 replicative capacity in early and advanced infection

AIDS

Volumn 13, Issue 1, 1999, Pages 67-73

  Phillips, Andrew N ^a   McLean, Angela R ^b   Loveday, Clive ^a   Tyrer, Mervyn ^a   Bofill, Margarita ^a   Devereux, Helen ^a   Madge, Sara ^a   Dykoff, Angela ^a   Drinkwater, Anthony ^a   Burke, Andrew ^a   Huckett, Louise ^a   Janossy, George ^a   Johnson, Margaret A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b INSTITUT PASTEUR   (France)

Author keywords

Antiretroviral therapy; CD4 lymphocyte count; Drug resistance; Dynamics; Mathematical models; Pathogenesis; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ARTICLE; CLEARANCE; CLINICAL ARTICLE; DISEASE COURSE; DYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LABORATORY TEST; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; VIRUS REPLICATION;

HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION;

EID: 0032987632     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199901140-00009     Document Type: Article

References (32)

1. 1. Lane HC, Masur H, Gelmann EP, et al.: Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med 1985, 78:417-422.
2. 2. Phillips AN, Lee CA, Elford J, et al.: Serial CD4 lymphocyte counts and the development of AIDS. Lancet 1991, 337:389-392.
3. 3. Weiss RA: How does HIV cause AIDS? Science 1993, 260:1273-1279.
4. 4. McLean AR: The balance of power between HIV and the immune system. Trends Microbiol 1993, 1:9-13.
5. 5. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995, 267:483-489.
6. 6. Shenzle D: A model for AIDS pathogenesis. Stat Med 1994, 13:2067-2079.
7. 7. Essunger P, Perelson AS: Modelling HIV infection of CD4+ T-cell subpopulations. J Theor Biol 1994, 170:367-391.
8. 8. Asjö B, Morfeldt-Manson L, Albert J, et al.: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986, ii:660-662.
9. 9. Fenyö E-M, Albert J, Asjö B: Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989, 3 (suppl 1):S5-S12.
10. 10. Tersmette M, Lange JM, de Goede RE, et al.: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989, i:983-985.
11. 11. Cheng-Mayer C, Seto D, Tateno M, Levy JA: Biologic features of HIV that correlate with virulence in the host. Science 1988, 240:80-82.
12. 12. Fouchier RAM, Meyaard L, Brouwer M, Hovenkamp E, Schuitemaker H: Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo. Virology 1996, 219:87-95.
13. 13. Connor RI, Ho DD: Human immunodeficiency virus type-1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994, 68:4400-4408.
14. 14. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of HIV-1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992, 66:1354-1360.
15. 15. Miedema F, Tersmette M, van Lier RA: AIDS pathogenesis: a dynamic interaction between HIV and the immune system. Immunol Today 1990, 11:293-297.
16. 16. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997, 185:621-628.
17. 17. McLean AR, Nowak MA: Models of interactions between HIV and other pathogens. J Theor Biol 1992, 155:69-86.
18. 18. Walker CM, Moody DJ, Stites DP, Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
19. 19. Landay AL, Mackewicz C, Levy JA: An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993, 69:106.
20. 20. Levy JA, Mackewicz CE, Barker E: Controlling HIV pathogenesis: the role of the non-cytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996, 17:217-224.
21. 21. Phillips AN, McLean A, Johnson MA, et al.: HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. J Med Virol 1997, 53:261-265.
22. 22. Peakman M, Mahalingham A, Pozniak A, et al.: Makers of immune cell activation and disease progression. In Cell Activation and Apoptosis in HIV Infection. Edited by Andrieu JM, Lu W. New York: Plenum Press; 1995.
23. 23. Hammer S, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
24. 24. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG: Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J Immunol 1989, 142:773-780.
25. 25. Stevenson M, Brichacek B, Heinzinger N, et al.: Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. Adv Exp Med Biol 1995, 374:33-45.
26. 26. Cozzi Lepri A, Sabin CA, Phillips AN, et al.: Investigating temporal changes in the rate of HIV progression: challenges and limitations. AIDS 1997, 11:1647-1649.
27. 27. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387:188-191.
28. 28. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
29. 29. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
30. 30. Stellbrink HJ, Zöller B, Fenner T, et al.: Rapid plasma virus and CD4+ T-cell turnover in HIV infection: evidence for an only transient interruption by treatment. AIDS 1996, 10:849-857.
31. 31. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
32. 32. Neumann A, Tubiana R, Calvez V, Robert C, Autran B, Katlama C: Multi-phasic HIV decline following triple antiretroviral therapy is correlated with viral rebound dynamics during therapy interruption. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 517].